ZEV BIOTECH

World class Molecular Diagnostics for everyone, everywhere.

Zev-biotech
zevbiotech.com
mirisarri@zevbiotech.com

Diagnosis based on Molecular biology surpasses traditional clinical diagnosis in its ability to accurately diagnose genetic and infectious diseases and pharmacogenomics, making it an essential cornerstone of Personalized Medicine. **But only 5% of people around the world have access to molecular biology tests.**

ZEV developed a unique, complete molecular diagnostics platform for Personalized Medicine that any lab in the world can afford.

The Problem

Molecular Diagnostics is only available to a minority. Everywhere, a few, large labs centralize molecular diagnostics, or in countries without access to the technology, samples are sent abroad for analysis. This happens because:

- Equipment is hard to purchase, operate and maintain.
- Cost of the kit.
- Existing solutions require grouping hundreds of patients with the same disease to be cost effective.

These make it infeasible for Public Health systems, Insurances and the majority of the population to include molecular diagnostics in their plans.

The Solution

We built an innovative platform named IRIS®, that solves ***all problems of existing technologies at once***. By integrating proprietary reagents, hardware, and software into a single solution, IRIS empowers hospital (our clients) to offer molecular diagnostics to patients.

With its unique blend of cutting-edge technology, versatility, flexibility, scalability, and simplicity, IRIS is easy and cost-effective to implement in everywhere, making personalized medicine truly accessible to the word.

Business Model (B2B)

ZEV Biotech is a Consolidated Start-up

- Multidisciplinary **team**
- **IRIS**: has already developed & validated
- **Kits**: 2 kits approved by the Argentinean Regulatory Agency (ANMAT, like FDA)
- **Infrastructure**: R&D Lab and Manufacturing plant in Argentina
- Portfolio of **Intellectual Property**
- **Clients in Argentina**: a Chamber of Diagnostics Laboratories and 1 lab
- **Agreements in Argentina**: the Italian Hospital of Bs As, INVERA, the National Health Administration (ANLIS-Malbran) and National Institute of Agricultural Technology (INTA).

Next Steps

- **New Kits**: validate two kits already developed to identify:
  - Antimicrobial Resistant Genes
  - Bovine Leukemia Virus in cattle
- **Intellectual Property**: submit
- IRIS® Microarray Biochips Production Capability
- IRIS® All in One integrated **Hardware equipment**
- **Brazil**: consolidate presence with an R&D laboratory and production plant. Strategic partnership with Loccus and a public institute for antimicrobial resistance (CEPID-ARIES)
- **Sales**: roll out Q3 of 2026 (Argentina & Brazil)

Supported by:
IDB Inter-American Development Bank
GRIDX

The Team

Gilberto Ugalde
Partner

Maxi Irisarri, PhD.
Founder

Plus another 7 Scientists